While PrRP31 analogues with dual GPR10-NPFF2R agonism might show potential as novel anti-obesity agents, preclinical evidence indicate that NPFF2R also plays a role in central cardiovascular control55. Here, PRLHR is linked to obesity due to melanocortin 4 receptor deficiency.